大洋生物: 关于使用部分闲置募集资金进行现金管理到期赎回并继续进行现金管理的进展公告

Core Viewpoint - The company has announced the continued use of idle raised funds for cash management, aiming to enhance fund utilization efficiency while ensuring that the funds required for project construction are not affected [2][4]. Group 1: Cash Management Progress - The company has redeemed a financial product purchased with idle raised funds, amounting to 17 million yuan, and has earned a return of 193,900 yuan, which has been fully deposited into the special account for raised funds [3]. - The company plans to use up to 140 million yuan of idle raised funds for cash management within 12 months from the board's approval date [2][4]. Group 2: Financial Product Details - The company has invested in a structured deposit product with a principal of 17 million yuan, with an expected annualized return of 1.25% to 2.50% [3][5]. - As of the announcement date, the company and its subsidiaries have 120 million yuan of idle raised funds in cash management that have not yet matured, which is within the authorized limit set by the board [5]. Group 3: Impact on the Company - The cash management of idle raised funds is expected to improve fund efficiency and generate investment returns for the company and its shareholders, without impacting the construction of fundraising projects [4][5].